Skip to main content
. Author manuscript; available in PMC: 2023 Mar 6.
Published in final edited form as: Clin Nucl Med. 2022 Dec 7;48(2):126–131. doi: 10.1097/RLU.0000000000004483

Table 5 –

Follow-up time for RFS analysis (see figure 4), stratified by FDG-PET/CT SUVmax result

SUVmax N Median follow-up time (IQR, range), months
Positive (≥ 1.8) 142 23.7 (10.7–25.1, 0–35.6)
Negative (< 1.8) 66 24.2 (17.5–25.5, 0–34.6)
Total 208 23.9 (12.4–25.2, 0–35.6)

IQR, interquartile range; RFS, recurrence-free survival.